CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM113637
035-os BibID:(scopus)85160402060 (wos)000998417200001
Első szerző:Vodicska Barbara
Cím:Correction to : Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors / Vodicska Barbara, Déri Júlia, Tihanyi Dóra, Várkondi Edit, Kispéter Enikő, Dóczi Róbert, Lakatos Dóra, Dirner Anna, Vidermann Mátyás, Filotás Péter, Szalkai-Dénes Réka, Szegedi István, Bartyik Katalin, Gábor Krisztina Míta, Simon Réka, Hauser Péter, Péter György, Kiss Csongor, Garami Miklós, Peták István
Dátum:2023
ISSN:1708-8569 1867-0687
Megjegyzések:In the original publication, there are few errors in the figures. The corrections are as follows: Figure 1f: At the SUM row, numbers were missing. They have been added [35 (blue bar) and 18 (orange bar)] as they were originally in the manuscript. Figure 2b: scale, y axis had 00 instead of 20. The corrected figure has 20 as it was originally in the manuscript. Figure 2d: lower left panel?figure part indication was missing. Figure part indicator "d" has been added as it was originally in the manuscript. Figure 2d: scale, y axis had 00 instead of 20. The corrected figure has 20 as it was originally in the manuscript. Figure 2g: scale, y axis had 00 instead of 20. The corrected figure has 20 as it was originally in the manuscript. Figure 3a: scale, y axis had 00 instead of 20. The corrected figure has 20 as it was originally in the manuscript. Figure 3c: scale, y axis had 00 instead of 20. The corrected figure has 20 as it was originally in the manuscript. Figure 3c: under the first bar, x axis, category II, there was n?=?34 instead of n?=?7. The corrected figure now has n?=?7 as it was originally in the submitted manuscript. Figure 5a: ARHGEF1-2 was originally ARHGEF12. In the corrected version it is now accurately displayed as ARHGEF12. Figure 5a: "NG S50" has been changed to "NGS 50" at 2 occurrences. Figure 5a: in the Panel column, LB-AIO has been changed to LB-600 at 2 occurrences to align with figure legends. Figure 5b header: "DNA damage raesponse" has been corrected to "DNA damage response" as originally submitted. Figure 5 a, b and c parts: "MARK" has been corrected to "MAPK" all the three occurrences as originally submitted. Figure 5b: At patient ID 83 and 76 original data has been lost during figure editing. The panels WES and FISH, respectively have been reverted to NGS-600 to align with figure legends and research results. Figure 5b: At patient ID 19, original data have been lost during figure editing. The panel FISH now has been reverted to WES to align with research results as originally submitted. Figure 5c: At patient ID 13, original data have been lost during figure editing. The panel FISH now has been reverted to WES to align with research results as originally submitted. Besides, the corrected figures are as follows: (Figure presented.) (Figure presented.) (Figure presented.) (Figure presented.) Figure 1 Figure 2 Figure 3 Figure 5 The original article has been corrected. ? 2023, The Author(s).
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:World Journal of Pediatrics. - [Epub ahead of print] (2023). -
További szerzők:Déri Júlia Tihanyi Dóra Várkondi Edit Kispéter Enikő Dóczi Róbert Lakatos Dóra Dirner Anna Vidermann Mátyás Filotás Péter Szalkai-Dénes Réka Szegedi István (1969-) (hematológus, onkológus, nefrológus) Bartyik Katalin (haematológus) Gábor Krisztina Míta Simon Réka Hauser Péter Péter György Kiss Csongor (1956-) (hematológus, onkológus) Garami Miklós Peták István
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM109812
035-os BibID:(scopus)85149918954
Első szerző:Vodicska Barbara
Cím:Real-world performance analysis of a novel computational method in the precision oncology of pediatric tumors / Vodicska Barbara, Déri Júlia, Tihanyi Dóra, Várkondi Edit, Kispéter Enikő, Dóczi Róbert, Lakatos Dóra, Dirner Anna, Vidermann Mátyás, Filotás Péter, Szalkai-Dénes Réka, Szegedi István, Bartyik Katalin, Gábor Krisztina Míta, Simon Réka, Hauser Péter, Péter György, Kiss Csongor, Garami Miklós, Peták István
Dátum:2023
ISSN:1708-8569 1867-0687
Megjegyzések:Background The utility of routine extensive molecular profling of pediatric tumors is a matter of debate due to the high number of genetic alterations of unknown signifcance or low evidence and the lack of standardized and personalized deci sion support methods. Digital drug assignment (DDA) is a novel computational method to prioritize treatment options by aggregating numerous evidence-based associations between multiple drivers, targets, and targeted agents. DDA has been validated to improve personalized treatment decisions based on the outcome data of adult patients treated in the SHIVA01 clinical trial. The aim of this study was to evaluate the utility of DDA in pediatric oncology. Methods Between 2017 and 2020, 103 high-risk pediatric cancer patients (<21 years) were involved in our precision oncol ogy program, and samples from 100 patients were eligible for further analysis. Tissue or blood samples were analyzed by whole-exome (WES) or targeted panel sequencing and other molecular diagnostic modalities and processed by a software system using the DDA algorithm for therapeutic decision support. Finally, a molecular tumor board (MTB) evaluated the results to provide therapy recommendations. Results Of the 100 cases with comprehensive molecular diagnostic data, 88 yielded WES and 12 panel sequencing results. DDA identifed matching of-label targeted treatment options (actionability) in 72/100 cases (72%), while 57/100 (57%) showed potential drug resistance. Actionability reached 88% (29/33) by 2020 due to the continuous updates of the evidence database. MTB approved the clinical use of a DDA-top-listed treatment in 56 of 72 actionable cases (78%). The approved therapies had signifcantly higher aggregated evidence levels (AELs) than dismissed therapies. Filtering of WES results for targeted panels missed important mutations afecting therapy selection. Conclusions DDA is a promising approach to overcome challenges associated with the interpretation of extensive molecular profling in the routine care of high-risk pediatric cancers. Knowledgebase updates enable automatic interpretation of a con tinuously expanding gene set, a "virtual" panel, fltered out from genome-wide analysis to always maximize the performance of precision treatment planning
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:World Journal of Pediatrics. - [Epub ahead of print] (2023). -
További szerzők:Déri Júlia Tihanyi Dóra Várkondi Edit Kispéter Enikő Dóczi Róbert Lakatos Dóra Dirner Anna Vidermann Mátyás Filotás Péter Szalkai-Dénes Réka Szegedi István (1969-) (hematológus, onkológus, nefrológus) Bartyik Katalin (haematológus) Gábor Krisztina Míta Simon Réka Hauser Péter Péter György Kiss Csongor (1956-) (hematológus, onkológus) Garami Miklós Peták István
Pályázati támogatás:NVKP_16-1-2016-0005
Egyéb
KFI_16-1-2016-0048
Egyéb
NKFIH K_22 143021
NKFIH
2019-1.1.1-PIACI-KFI-2019-00367
Egyéb
K_143021
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1